Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 34.00p 32.00p 36.00p 34.00p 34.00p 34.00p 7,003 06:30:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.7 -7.9 -9.3 - 23.46

Avacta Share Discussion Threads

Showing 3576 to 3600 of 3600 messages
Chat Pages: 144  143  142  141  140  139  138  137  136  135  134  133  Older
DateSubjectAuthorDiscuss
24/5/2018
09:07
Back to Avacta - looks like a dead cat bounce before the next fundraise...…..
banksy9
24/5/2018
09:04
MIPs look interesting but are still a very long way from the clinic, I suspect...…230;..
banksy9
23/5/2018
08:41
I have previously highlighted MIPs Diagnostics on here, so I believe the following is noteworthy - Dr. Adrian Kinkaid, CEO of MIPs Diagnostics Adrian has extensive experience in the life sciences sector, with particular expertise in affinity reagents, including antibodies, affimers and aptamers. He has developed a thorough understanding of the field and considers MIPs as a cost effective and high quality alternative to existing reagents due especially to their robustness and speed of development. Prior to joining MIP Diagnostics, Adrian worked as Chief Commercial Officer for Promexus, a protein biotherapeutics company based on affimer technology from Avacta Life Sciences. Before this he was Head of Technology Access and then Strategic Market Development Leader for Abcam, the leading provider of research antibodies. Mercia further invests in MIPs Diagnostics (another potential game changer in Mercia's portfolio that's on my watch list!) - ‘Synthetic antibody’ firm MIP Diagnostics secures £1.5m By Tess Egginton - 9th May 2018 A Midlands-based life sciences company which develops synthetic alternatives to antibodies has closed a £1.5m Series A funding round supported by Mercia Fund Managers and a number of private investors. The investment will allow MIP Diagnostics to expand its team, set up new production facilities and develop its own products to sell under license. New antibodies can take months to make and the process can be unreliable, as it involves ‘challenging’ cells with an antigen or foreign molecule in the hope that it will produce the right antibodies. By contrast MIPs are synthesized in a laboratory and can be created in days. They are also more cost-effective and much more stable than antibodies, with a longer shelf-life and can be used in conditions where antibodies just will not function. Full story - https://tinyurl.com/Synthetic-Antibodies Also not widely reported, is that David Evan's is another new investor in MIPs - https://tinyurl.com/MIPs-Angel-Investors
wan
22/5/2018
16:36
Weak holders getting out on the bounce and day traders grabbing a small profit - Do I smell buring fingers from all who bought at 34p and above ?? Could this ramp up and fall back suggest a placing might be round the corner or am I just paranoid?
pugugly
22/5/2018
08:28
More promising studies, but no deal yet
18bt
16/5/2018
18:21
More importantly,there are no deals being done. Despite the bullish statements from the Company. Maybe the Directors should have another look a the "YELLOW BOOK."
lantanatony
16/5/2018
16:35
It says the company can't convince enough shareholders not to want to sell and/or enough new shareholders to buy. Simple.
banksy9
14/5/2018
21:06
Come on now avacta this is silly, what does this sort of share price say about the running of the company?? Not good. I would get it sorted. Thats my very strong advice indeed. Nudge Nudge Wink Wink!!!!
escapetohome
11/5/2018
17:35
Here's the answer: www.capitalnetwork.com/companies/research/110600/avacta-group-rapid-progress-of-immuno-oncology-programs-110600.html. "Stock price weakness reflects in our view uncertainty around a likely capital raise before year end". So, if they need another 2-years' cash to get to the clinic in 2020 they will need another £20m or so, which is about another 50% dilution or so........
banksy9
10/5/2018
09:54
Who knows? I suspect the elephant in the room might well be the need to raise more capital but that's just a guess. The question is how much and a what price.......? Thoughts? It gets very expensive in the clinic!
banksy9
09/5/2018
22:46
With the shares below thirty pence. When can we expect some proactive reaction from the Directors!?
lantanatony
02/5/2018
05:25
Agreed, the Prof. needs to do some deals or step aside to get a commercial leader in ASAP.
banksy9
30/4/2018
08:21
Yes ,Avacta need to stop talking and start doing. If they ever needed a deal it's now.
lantanatony
28/4/2018
19:08
Yes they originally promised a revenue-generation story with web-based sales that never materialised and then flipped into a therapeutic story but still 2 years from the clinic. I'd wait for a very good discount at the next fundraise........
banksy9
27/4/2018
07:40
And yet they have been many many years on aim already, but its as though they just got a listing with their science. Time to buy?
escapetohome
27/4/2018
04:03
Oil and water, my friend, although I'm not suggesting which is the oily side! This looks like a classic academic spinout with good science that has come on to AIM too early. Investors want it to be a revenue-generating business when more research is required to hit a serious value inflection point. The problem is they'll need a lot of cash by the looks of it. Prepare for mega dilution guys!
banksy9
24/4/2018
16:10
Academia and business just don't seem compatible!?
lantanatony
18/4/2018
20:16
Liked that
ffp
18/4/2018
20:15
I agree with Poacher: Professor Smith likes to talk the talk on the webcam, burn the cash but can't do deals whatever the technology. As they say, you can take the academic out the lab but you can't take the lab out the academic! Look like another fund raising is on the way and the cycle starts all over again. DD
dickdastardly1
17/4/2018
14:46
Crazy! Avacta raised their funding at £1,20. What do you think those investors think ?
lantanatony
17/4/2018
12:49
You wouldnt think so at all. I think it should be recognised that some progress has been made. Perhaps not financially, but sadly some investors are churning out the negative record, solely because they bought at much higher prices!!!!!!!!!!!
escapetohome
17/4/2018
12:41
What's your point? We know all about this stuff!
lantanatony
16/4/2018
22:57
packages. -- Solid progress with partners: -- Positive outcome of initial trial with Glythera Ltd. leading to a new drug development partnership for Affimer drug conjugates. -- Research collaboration with FIT Biotech Oy established to demonstrate effectiveness of the combined technologies for gene delivered Affimer therapeutics: data expected shortly. -- Moderna research collaboration has a natural three-year termination date at the end of May 2018 and the Group anticipates delivering Affimer assets to Moderna for development by that date or under an extension to the agreement. -- Continuing collaboration with Memorial Sloan Kettering Cancer Center CAR-T on proof-of-concept study: the Group continues to work to generate Affimer binders to the target of interest. -- Collaboration established with OncoSec (NASDAQ: ONCS) on innovative gene delivery of therapeutic Affimers: third partnership to explore gene delivery with Affimers reflects significant interest received for this application.
escapetohome
16/4/2018
22:56
Excellent progress with second immuno-oncology programme, a LAG3 blockade, which can be combined with PD-L1 for improved efficacy. -- Discovery programme continues to deliver a pipeline of Affimer binders to other important immuno-oncology targets for future partnering or development. -- Very positive pharmacokinetic data obtained in mouse for Affimer XT(TM) half-life extension platform. -- Continued platform validation and de-risking through completion of a number of in-vitro data packages.
escapetohome
16/4/2018
22:33
Bearing in mind this is the only real financial commitment..... "- Moderna research collaboration has a natural three-year termination date at the end of May 2018 and the Group anticipates delivering Affimer assets to Moderna for development by that date or under an extension to the agreemen " What happens if no extension? It's game over imho. For clarity,I would like to take a small punt here but will not do so without the Moderna continuity.
spekky
Chat Pages: 144  143  142  141  140  139  138  137  136  135  134  133  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180528 05:27:14